|
| 摘要: |
| 目的综述抗体导向的酶催化前体药物疗法（Antibody directed enzyme prodrug therapy，ADEPT）的研究进展，评价这种技术应用的潜力。方法检索近几年国内外研究ADEPT的相关文献，并进行分析、归纳。结果“抗体导向的酶催化前体药物疗法”是一种肿瘤靶向治疗两步策略。该策略以巧妙的设计克服了以往单抗作为药物载体的许多缺陷，通过分子与分子靶标，酶与底物（前药）的双重选择性，提高药物对肿瘤细胞的靶向性, 降低毒性, 克服耐药性。结论抗体导向的酶催化前体药物疗法是一种极有发展前途的肿瘤靶向疗法。 |
| 关键词: 抗体导向的酶催化前体药物疗法 肿瘤靶向 |
| DOI： |
| 分类号: |
| 基金项目: |
|
| Antibody Directed Enzyme Prodrug Therapy |
|
ZHANG Xinping
|
| Abstract: |
| OBJECTIVE This review presents the background and the development of antibody-directed enzyme prodrug therapy(ADEPT), and evaluates the application potential of the technology. METHODS This review analyzes and summarizes the related literatures in recent years. RESULTS ADEPT is a novel therapeutic approach that targets an enzyme into tumors to convert a relatively nontoxic prodrug into an active cytotoxic agent. This method has a number of advantages, including the reduction of systemic toxicity. CONCLUSION ADEPT is a promosing technique for the cancer target therapy. |
| Key words: antibody directed enzyme prodrug therapy tumor targeted |
